# Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

> **NCT05086744** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)
- Cold Agglutinin Disease (CAD)

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT05086744
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-21
- **Primary completion:** 2023-09-20
- **Final completion:** 2024-05-17
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05086744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05086744, "Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05086744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*